Muscoril (Thiocolchicoside)

Thiocolchicoside, the active ingredient in Muscoril, is a muscle relaxant presented as an injectable formulation for intramuscular use. It treats muscle spasm and musculoskeletal pain in adult patients. GNH USA supplies Muscoril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Muscoril is a skeletal muscle relaxant that acts on the glycine receptor pathway to alleviate conditions characterized by involuntary muscle contraction. - Muscle spasm: reduces the intensity and frequency of painful muscle contractions. - Musculoskeletal pain: eases discomfort associated with strain or injury of muscles and joints. - Acute low back pain: provides short‑term relief by relaxing paraspinal muscles.

Adverse reactions may occur with Muscoril use.

Common Side Effects: - Dizziness - Drowsiness - Nausea - Headache - Injection‑site pain - Gastrointestinal upset

Serious or Rare Side Effects: - Allergic reactions (rash, angioedema) - Hepatotoxicity - Severe hypotension - Seizures - Agranulocytosis - Stevens‑Johnson syndrome

Muscoril should be used with attention to patient‑specific factors and proper handling. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; consider risk versus benefit. - Renal impairment: use with caution and monitor renal function. - Hepatic impairment: dose adjustment may be required. - Elderly: increased sensitivity to sedative effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Potential drug interactions require assessment before initiating Muscoril therapy.

Major Interactions (Avoid): - CNS depressants: additive sedation and respiratory depression. - MAO inhibitors: risk of severe hypotension. - Other muscle relaxants: heightened muscle weakness.

Moderate Interactions (Monitor Closely): - Anticoagulants: possible increased bleeding tendency. - Diuretics: may exacerbate electrolyte disturbances. - Hepatically metabolised antibiotics: altered plasma levels of thiocolchicoside.